Cart
sales@molnova.com
(Z)-SU14813
CAS No. 452105-23-6
(Z)-SU14813( —— )
Catalog No. M37572 CAS No. 452105-23-6
(Z)-SU14813 is a novel tyrosine kinase inhibitor with anticardiogenic and antitumor activity that inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent manner.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 459 | In Stock |
|
| 10MG | 657 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1386 | In Stock |
|
| 100MG | 1832 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(Z)-SU14813
-
NoteResearch use only, not for human use.
-
Brief Description(Z)-SU14813 is a novel tyrosine kinase inhibitor with anticardiogenic and antitumor activity that inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent manner.
-
Description(Z)-SU14813 is a novel tyrosine kinase inhibitor with anticardiogenic and antitumor activity that inhibits VEGFR-2, PDGFR-β, and FLT3 phosphorylation in xenograft tumors in a dose- and time-dependent manner.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayProteasome/Ubiquitin
-
TargetTyrosinase
-
RecptorTyrosinase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number452105-23-6
-
Formula Weight442.48
-
Molecular FormulaC23H27FN4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=C\1/C=2C(NC1=O)=CC=C(F)C2)\C3=C(C)C(C(NC[C@@H](CN4CCOCC4)O)=O)=C(C)N3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
P505-15 Acetate
P505-15 Acetate is a selective inhibitor of spleen tyrosine kinase that acts by suppressing leukocyte immune function and inflammation and leading to a reduction in arthritis score and attenuated histological damage.
-
KN-93
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII), competitively blocking CaM binding to the kinase.
-
Tafetinib
Tafetinib (SIM-010603) is a novel potent and orally available tyrosine kinase inhibitor with anti-angiogenic and anti-tumour activity.
